Background: There is currently a lack of evidence-based therapies that are safe and effective for plaque-type morphea. We aimed to evaluate the therapeutic potential and safety profile of imiquimod 5% cream in plaque-type morphea.
Methods: We enrolled 25 adult patients from two Canadian centers with histologically confirmed plaque-type morphea. Imiquimod 5% was applied to a representative plaque, and vehicle was applied to a control plaque for 9 months. Treatment efficacy was assessed with the Dyspigmentation, Induration, Erythema, and Telangiectasias (DIET) score, histology, and ultrasound evaluation.
Results And Conclusions: Twenty-two patients completed the entire length of the study. Imiquimod 5% was superior to vehicle in reducing DIET scores at 3, 6, 9, and 12 months (p < .05). Induration demonstrated the greatest response. Histologic evaluation showed significant improvement or resolution of disease. However, no ultrasonographic differences were found in dermal and hypodermal thicknesses between the treatment and vehicle groups (p > .05). Adverse effects were minimal and well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2310/7750.2014.14072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Histopathologic spectrum of morphea: a single-center retrospective study.
Dermatol Reports
September 2024
Department of Dermatology, Prof Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
Article Synopsis
- Morphea is a rare autoimmune disease affecting the skin and subcutaneous tissues, with this study analyzing 78 patients to explore its demographic, clinical, and histological characteristics between 2016 and 2022.
- The plaque type was the most common clinical presentation (87.5%), with significant histopathological findings such as complete homogenization of dermal collagen (100%) and significant loss of skin appendages (98.7%).
- Key observations included varying histopathological features and a notable association of certain signs in lower extremity lesions, suggesting morphea’s complex diagnosis may require careful clinical correlation.
Rapid Progression of Localized Morphea to Disseminated Plaque-Type Morphea Following COVID-19 Infection.
Dermatol Pract Concept
April 2023
Department of Pathology, Ardabil University of Medical Sciences, Ardabil, Iran.
Association between quality of life and clinical characteristics in patients with morphea.
Qual Life Res
October 2018
Department of Health Economics, Corvinus University Budapest, Fővám tér 8., Budapest, 1093, Hungary.
Background: Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients.
Objective: To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL.
Methods: A cross-sectional study has been carried out among adult morphea patients.
Juvenile Localized Scleroderma with Hyaline Deposits in the Renal Arteriole.
Case Rep Dermatol
April 2018
Department of Pediatrics, Japanese Red Cross Sendai Hospital, Taihaku-ku, Sendai, Japan.
We report a 10-year-old boy with localized scleroderma of the linear and plaque type, who showed proteinuria and hematuria. In this patient, skin, articular, and renal manifestations appeared successively and then began to resolve in the same order. A renal biopsy specimen demonstrated mild mesangial cell proliferation, exudate of immunoglobulin in the glomerular capillary, and large electron-dense deposits in the afferent arteriole.
View Article and Find Full Text PDFThe effects of many dermatologic syndromes are not exclusive to the skin. Disorders commonly involve a complex interplay between multiple organ systems, thus not relying solely on the dermatologist for proper work up, diagnosis, and treatment. Morphea is one such rare disease which involves progressive loss or atrophy of subcutaneous tissue, muscle, and bone with a relatively mysterious etiology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!